Vonaprument Phase III trial in geographic atrophy shows promise for vision preservation
核心洞察
Annexon's vonaprument (搜索) demonstrated strong, dose-dependent vision preservation in geographic atrophy (搜索) alongside a robust safety profile in late-stage development.
The Phase III program is described as well-powered, with high patient retention and compliance supporting the strength of the trial design.
The company's GBS program is also advancing toward regulatory filings, according to the conference presentation.
Annexon, Inc. reported late-stage progress for vonaprument (搜索) in geographic atrophy (搜索) (GA), with the therapy showing strong, dose-dependent vision preservation and a robust safety profile. The update was presented during the 12th Annual Cantor Fitzgerald Global Healthcare Conference.
The Phase III trials for vonaprument (搜索) are described as well-powered, with high retention and compliance among participants. The conference also highlighted late-stage progress across neuroinflammatory disease therapies, with the company's GBS program advancing toward regulatory filings.
Source: Vonaprument's phase III trial in GA shows promise for vision preservation and broad market impact